The Chatbot Arrived Before the Seatbelt

Acronyms used: LLM means Large Language Model, an AI system trained to generate text and other outputs by learning patterns in language. AI means Artificial Intelligence. RCT means Randomized Controlled Trial, a study design where people are assigned to groups for fair comparison. FDA means Food and Drug Administration. SaMD means Software as a Medical Device. EHR means Electronic Health Record. HIPAA means Health Insurance Portability and Accountability Act. API means Application Programming Interface.

The chatbot arrived before the seatbelt.

That is the problem. Not that LLMs are useless. They are useful. Not that every chatbot is a villain in a clean interface. That is too easy. The problem is that persuasive conversational software has been placed in front of children, lonely adults, anxious patients, overworked staff, and people in fragile moments before society has learned how to test it with the seriousness the setting deserves.

A pill does not get that freedom. It is tested in stages. It is studied for dose, effect, side effects, warnings, and failure modes. The comparison is imperfect because a pill enters the bloodstream and a chatbot enters a conversation. But that difference makes the issue sharper, not softer. Conversation changes attention, trust, belief, dependence, and judgment.

Some LLMs are being wrapped as companions, coaches, tutors, support agents, clinical assistants, office helpers, and always-available listeners. The same engine that summarizes a meeting can sit with a teenager at night. The same model that drafts an email can also answer a frightened medical question. The same product that feels charming in a demo can become part of someone’s daily emotional scaffolding.

That is not a toy problem.

At internet scale, rare failures stop being rare in human terms. A tiny failure rate across millions of users becomes a crowd. Edge cases are no longer edges when the product is everywhere. A company may call a bad interaction an anomaly. A family, a school, a clinic, or a regulator may call it evidence that the guardrail was decorative.

The deeper danger is not only hallucination, although confident falsehood matters. The deeper danger is misplaced trust. LLMs can flatter, agree, soften, extend, and keep a conversation alive. That can be helpful in ordinary drafting or brainstorming. In vulnerable settings, it can become a velvet trap. A good human listener sometimes interrupts. A good clinician sometimes refuses the user’s framing. A good teacher notices confusion beneath fluent words. A chatbot sees text and generates the next turn.

Classification is not care.

This is why testing has to include long conversations, ambiguous statements, mixed languages, slang, anger, loneliness, fear, children, low-literacy users, and people who do not announce risk in neat terms. Real users speak sideways. They joke. They hint. They test whether anyone is listening. A safety system that only recognizes clean textbook phrases is not safe enough for the messier parts of life.

Sensitive AI uses need something like a clinical-trial mentality, even when the literal regulatory pathway differs. Before a chatbot is trusted in high-stakes roles, it should be tested in realistic conditions. Not only by engineers writing clever prompts in a conference room. Not only by internal red teams. Not only by polished benchmark suites that turn human suffering into tidy rows. It needs independent evaluation, incident reporting, audit trails, version tracking, escalation design, and a clear answer to the old boring question: who is responsible when this fails?

The boring machinery matters.

Seatbelts are boring. Fire codes are boring. Audit logs are boring. In healthcare, many useful protections are dull by design. The public likes the miracle story; systems survive by checklists, labels, review, and ownership. LLMs need some of that dullness around them, especially when aimed at health, children, crisis support, elder care, legal rights, finance, or emotional dependency.

The business incentive points in the opposite direction. Engagement is profitable. A warm bot that keeps people talking is easier to monetize than a cautious bot that breaks character, refuses a premise, and tells the user to seek real-world help. Safety often interrupts the spell. That interruption is exactly why it is needed.

The right question is not whether AI is good or bad. The right question is: good for what, for whom, under what evidence, with what supervision, and what happens when it is wrong?

For low-risk tasks, LLMs are often fine. Draft the email. Summarize the policy. Explain a concept. Translate bureaucratic language into plain English. Make the machine carry the sacks of verbal cement.

For medium-risk tasks, slow down. If an LLM summarizes a medical record, a legal letter, a school complaint, or a financial document, a responsible human should review the output carefully. Not glance at it while half-listening to a phone notification. Review it.

For high-risk tasks, the standard must be much higher. Clinical triage, child-facing companionship, crisis response, elder support, legal rights, financial distress, abuse disclosure, and care planning are not playgrounds for “move fast and patch later.” Moving fast in these settings means the cost of learning is paid by someone else.

There is a practical path. Label systems clearly. Restrict child-facing behavior. Make age protections more than theater. Require independent safety audits. Track incidents. Test after model updates. Create escalation paths. Keep logs where consequences are serious. Make SaMD claims go through the appropriate regulatory discipline. Make HIPAA and privacy responsibilities explicit when health data enters the system. Make companies prove more than fluency.

This does not mean freezing all use. LLMs can help students, doctors, researchers, patients, clerks, small businesses, and tired writers in rooms with unreliable fans and cooling tea. The usefulness is real. But usefulness is not immunity.

The future will be messy. People will use these tools for comfort because real comfort is expensive, unavailable, or asleep. Clinicians will use them because paperwork keeps multiplying. Companies will sell companionship because attention is valuable. Regulators will arrive late. Some systems will help greatly. Some will harm quietly. Some harms will be denied until they become public.

The point is not to be anti-AI. The point is to be anti-carelessness.

If society demands evidence before approving a chemical that changes the body, it should not shrug at a conversational machine that changes trust, dependency, and belief. The companies know enough to advertise wonder. They should know enough to prove safety. Until then, the chatbot should be treated as software: sometimes brilliant, sometimes useful, sometimes dangerous, and never automatically worthy of the role its voice seems to claim.